Safe and effective: Anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis

C. J. Kiely; K. Subramaniam; J. Platten; P. Pavli

doi:10.1111/imj.13057

Safe and effective: Anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis

C. J. Kiely^*, K. Subramaniam, J. Platten, P. Pavli

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Biological therapy, particularly the anti-tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients with inflammatory bowel diseases (IBD). We present 21 pregnancies in IBD patients exposed to anti-TNF agents between 2007 and 2014. Our study demonstrates that anti-TNF therapy is safe and effective in pregnancy. Rates of foetal complications are similar to IBD cohorts from the pre anti-TNF era.

Original language	English
Pages (from-to)	616-619
Number of pages	4
Journal	Internal Medicine Journal
Volume	46
Issue number	5
DOIs	https://doi.org/10.1111/imj.13057
Publication status	Published - 1 May 2016

Access to Document

10.1111/imj.13057

Cite this

@article{3c25d33963f54f099fea8d50966e93d6,

title = "Safe and effective: Anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis",

abstract = "Biological therapy, particularly the anti-tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients with inflammatory bowel diseases (IBD). We present 21 pregnancies in IBD patients exposed to anti-TNF agents between 2007 and 2014. Our study demonstrates that anti-TNF therapy is safe and effective in pregnancy. Rates of foetal complications are similar to IBD cohorts from the pre anti-TNF era.",

keywords = "Crohn disease, Inflammatory bowel disease, Pregnancy, Tumour necrosis factor-alpha, Ulcerative colitis",

author = "Kiely, {C. J.} and K. Subramaniam and J. Platten and P. Pavli",

note = "Publisher Copyright: {\textcopyright} 2016 Royal Australasian College of Physicians.",

year = "2016",

month = may,

day = "1",

doi = "10.1111/imj.13057",

language = "English",

volume = "46",

pages = "616--619",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Safe and effective

T2 - Anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis

AU - Kiely, C. J.

AU - Subramaniam, K.

AU - Platten, J.

AU - Pavli, P.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Biological therapy, particularly the anti-tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients with inflammatory bowel diseases (IBD). We present 21 pregnancies in IBD patients exposed to anti-TNF agents between 2007 and 2014. Our study demonstrates that anti-TNF therapy is safe and effective in pregnancy. Rates of foetal complications are similar to IBD cohorts from the pre anti-TNF era.

AB - Biological therapy, particularly the anti-tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients with inflammatory bowel diseases (IBD). We present 21 pregnancies in IBD patients exposed to anti-TNF agents between 2007 and 2014. Our study demonstrates that anti-TNF therapy is safe and effective in pregnancy. Rates of foetal complications are similar to IBD cohorts from the pre anti-TNF era.

KW - Crohn disease

KW - Inflammatory bowel disease

KW - Pregnancy

KW - Tumour necrosis factor-alpha

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84969286786&partnerID=8YFLogxK

U2 - 10.1111/imj.13057

DO - 10.1111/imj.13057

M3 - Article

SN - 1444-0903

VL - 46

SP - 616

EP - 619

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 5

ER -

Safe and effective: Anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this